Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Johnson and Johnson
Mallinckrodt
Covington
Chinese Patent Office
Fuji
Cantor Fitzgerald
Farmers Insurance
AstraZeneca

Generated: May 23, 2018

DrugPatentWatch Database Preview

STAXYN Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Staxyn, and what generic alternatives are available?

Staxyn is a drug marketed by Bayer Hlthcare and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and thirty-nine patent family members in fifty-four countries.

The generic ingredient in STAXYN is vardenafil hydrochloride. There are five drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the vardenafil hydrochloride profile page.
Drug patent expirations by year for STAXYN
Pharmacology for STAXYN
Synonyms for STAXYN
2-(2-ethoxy-5-((4-ethylpiperazin-1-yl)sulfonyl)phenyl)-5-methyl-7-propylimidazo[5,1-f][1,2,4]triazin-4(1H)-one hydrochloride trihydrate
2-[2-ethoxy-5-(4-ethylpiperazin-1-yl)sulfonyl-phenyl]-5-methyl-7-propyl-1H-imidazo[5,1-f][1,2,4]triazin-4-one trihydrate hydrochloride
2-[2-ethoxy-5-(4-ethylpiperazin-1-yl)sulfonylphenyl]-5-methyl-7-propyl-1H-imidazo[5,1-f][1,2,4]triazin-4-one trihydrate hydrochloride
2-[2-ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]phenyl]-5-methyl-7-propyl-1H-imidazo[5,1-f][1,2,4]triazin-4-one trihydrate hydrochloride
330808-88-3
4146AH
4CH-016055
5M8S2CU0TS
785V904
A816221
AC1OCFGQ
AK143286
AKOS015895117
AKOS015966861
BAY-38-9456
C23H32N6O4S.ClH.3H2O
D03260
I06-0385
Imidazo[5,1-f][1,2,4]triazin-4(1H)-one,2-[2-ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]phenyl]-5-methyl-7-propyl-,hydrochloride, hydrate (1:1:3)
IN014948
KS-00000H95
KS-1318
Levitra
MFCD08458876
MolPort-003-986-627
MolPort-020-313-423
s2515
ST51052749
Staxyn (TN)
TL8001885
UNII-5M8S2CU0TS
Vardenafil HCl Trihydrate
Vardenafil hydrochloride
Vardenafil hydrochloride hydrate
Vardenafil hydrochloride hydrate (JAN)
Vardenafil hydrochloride trihydrate
Vardenafil Hydrochloride Trihydrate (Vivanza
VARDENAFILHYDROCHLORIDETRIHYDRATE(SUBJECTTOPATENTFREE)
X5251

US Patents and Regulatory Information for STAXYN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bayer Hlthcare STAXYN vardenafil hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 200179-001 Jun 17, 2010 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Bayer Hlthcare STAXYN vardenafil hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 200179-001 Jun 17, 2010 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Bayer Hlthcare STAXYN vardenafil hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 200179-001 Jun 17, 2010 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Paragraph IV (Patent) Challenges for STAXYN
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Orally Disintegrating Tablets 10 mg ➤ Subscribe 2011-12-22

Non-Orange Book US Patents for STAXYN

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,122,540 2-Phenyl substituted imidazotriazinones as phosphodiesterase inhibitors ➤ Try a Free Trial
6,566,360 2-phenyl substituted imidatriazinones as phosphodiesterase inhibitors ➤ Try a Free Trial
7,704,999 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors ➤ Try a Free Trial
7,314,871 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors, for treatment of hypertension ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Julphar
Harvard Business School
UBS
Deloitte
Healthtrust
AstraZeneca
US Army
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.